IDEAYA Q2 FY26 net loss widens to $112.45 million; revenue rises 35.02% to $8.86 million vs Q1 FY26

Reuters2026/08/04 10:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

IDEAYA Biosciences posted a net loss of $112.45 million, widening from $98.54 million in the prior quarter; loss per share deepened to $1.22 from $1.11.
Collaboration revenue rose 35.02% from the prior quarter to $8.86 million; R&D expenses increased to $108.69 million from $95.73 million.
Cash, cash equivalents, and marketable securities climbed to $1.24 billion at June 30 from $972.9 million at March 31, following $323.4 million in net offering proceeds.
OptimUM-02 trial of darovasertib plus crizotinib in metastatic uveal melanoma met its primary endpoint; NDA filing is underway with completion expected in H2 2026.
Management said the company is discussing an IDE849 Phase 3 registrational trial with the FDA, targeting initiation by end-2026; cash runway guidance into 2030 unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608040600PR_NEWS_USPR_____SF18271) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

IDEAYA Q2 FY26 net loss widens to $112.45 million; revenue rises 35.02% to $8.86 million vs Q1 FY26

You may also like

Crypto prices